Galapagos In-licenses Inflammatory Bowel Disease Drug Targets From Scipher Medicine

  • Scipher Medicine announced that Galapagos GLPG has exercised its option to in-license novel drug targets for inflammatory bowel disease (IBD) discovered by Scipher's Spectra platform.
  • In August 2020, Galapagos and Scipher Medicine agreed to jointly validate a suite of novel IBD targets discovered by Spectra. Galapagos has the exclusive option to in-license certain validated preclinical targets for further development and commercialization. 
  • After validation work, Galapagos is moving selected targets into the next phase of drug development, triggering a milestone payment to Scipher and making Scipher eligible to receive additional milestone-based payments.
  • Spectra is fueled by one of the largest patient molecular data lakes in autoimmune diseases and unique artificial intelligence network science-based algorithms. The platform identifies biologically similar patients and drug targets specific to those patients to improve response rates.
  • Price Action: GLPG shares are up 0.58% at $55.58 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!